Schistosomiasis

1. Front Matter

   Pages i-xi

   PDF

2. Schistosomes and Their Snail Hosts

   • Eric S. Loker, Gerald M. Mkoji

   Pages 1-11

3. Schistosome Retrotransposons

   • Paul J. Brindley, Claudia S. Copeland, Bernd H. Kalinna

   Pages 13-26

4. Gender-Specific Biology of Schistosoma Mansoni:

   • Philip T. LoVerde, Edward G. Niles, Ahmed Osman, Wenjie Wu

   Pages 27-43

5. Schistosoma Genomics

   • David L. Williams, Raymond J. Pierce

   Pages 45-64

6. Vaccine Development

   • Adrian P. Mountford, Stephen J. Jenkins

   Pages 65-79

7. The Surface of Schistosomes within the Vertebrate Host

   • Patrick J. Skelly

   Pages 81-100

8. The Application of DNA Microarrays in the Functional Genomic Study of Schistosome/Host Biology

   • Karl F. Hoffmann, Jennifer M. Fitzpatrick

   Pages 101-112

9. The Initiation of Host Immune Responses to Schistosome Egg Antigens

   • Edward J. Pearce

   Pages 113-124

10. Immunopathology in Experimental Schistosomiasis

    • Thomas Wynn A., Allen Cheever W., Mallika Kaviratne, Robert Thompson W., Margaret Mentink-Kane M., Matthias Hesse

    Pages 125-140

11. Immunological and other Factors Affecting Hepatosplenic Schistosomiasis Mansoni in Man

    • David W. Dunne, Mark Booth

    Pages 141-158

12. Pathways to Improved, Sustainable Morbidity Control and Prevention of Schistosomiasis in the People’s Republic of China

    • Donald P. McManus, Zheng Feng, Jiagang Guo, Yuesheng Li, Paul B. Bartley, Alex Loukas et al.

    Pages 159-175

13. Host Genetics and Schistosomiasis

    • Jeffrey M. Bethony, Jeff T. Williams

    Pages 177-190

14. Current and Future Antischistosomal Drugs

    • Donato Cioli, Livia Pica-Mattoccia

    Pages 191-206

15. Pubic Health Strategies for Schistosomiasis Control

    • Dirk Engels, Lorenzo Savioli

    Pages 207-222

16. Schistosomiasis: Are we Ready for A Coordinated Research and Public Health Agenda?

    • Daniel G. Colley

    Pages 223-232

17. Back Matter

    Pages 233-235

    PDF

Human schistosomiasis is a disease with a rich and well-documented past, and every expectation of an unfortunately long future. These infections were known to the ancient Egyptians and their transmission shows little evidence of slowing down, globally. The good news is that field applicable, and increasingly affordable, chemotherapy has been available for almost 25 years. Using chemotherapy and other means of control, some countries have decreased transmission and made excellent headway against morbidity. The bad news is that the public health problems caused by schistosomiasis are still with us, with the estimated number of cases of schistosomiasis, while shifting geographically, remaining approximately 200 million for the last 30 years. In fact, with the development of field usable ultrasound technology and meta-analyses performed on existing data, there is a new appreciation for the extent of non-lethal morbidity associated with these infections. While the percentage of individuals with severe hepatosplenic disease remains below 10%, recent reassessments of morbidity associated with schistosomiasis indicate that the prevelance of symptoms and the cost in diability-adjusted life years is much greater than was previously, commonly appreciated (Van der Werf, M. J. , et al. 2003, Acta Tropica 86:125-139; Charles H. King, personnel communication). Strong impetus for addressing these issues is provided by the World Health Assembly’s recently passed Resolution 54. 19, which calls for efforts to reduce morbidity caused by schistosomiasis and soil-transmitted helminths in school-aged children, largely through chemotherapy campaigns.

• Schistosomiasis
• antigen
• development
• infection
• vaccine
• infectious diseases

• Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, USA

  W. Evan Secor

• Center for Tropical and Emerging Global Diseases and Department of Microbiology, University of Georgia, USA

  Daniel G. Colley

Policies and ethics